

Accrual Summary for First Allogeneic Transplants in CRF and TED with Samples Available for Recipient and/or Donor through the NMDP for Adult Unrelated Donor Transplants

	Samples Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
Number of patients	26393	5867	4389
CRF	18009 (68)	4007 (68)	2971 (68)
TED	8384 (32)	1860 (32)	1418 (32)
Number of centers	228	199	268
Recipient age at transplant			
0-9	2742 (10)	607 (10)	656 (15)
10-19	2828 (11)	620 (11)	547 (12)
20-29	3118 (12)	665 (11)	572 (13)
30-39	3413 (13)	751 (13)	597 (14)
40-49	4367 (17)	985 (17)	707 (16)
50-59	9925 (38)	2239 (38)	1310 (30)
Median (range)	43 (0-84)	43 (0-79)	37 (0-76)
Recipient race / ethnicity			
Caucasian, non-Hispanic	22015 (85)	4874 (85)	3521 (84)
African-American, non-Hispanic	1250 (5)	295 (5)	233 (6)
Asian, non-Hispanic	559 (2)	134 (2)	126 (3)
Pacific Islander, non-Hispanic	38 (<1)	6 (<1)	4 (<1)
Native American, non-Hispanic	83 (<1)	20 (<1)	13 (<1)
Hispanic, Caucasian	1345 (5)	275 (5)	164 (4)
Hispanic, African-American	42 (<1)	14 (<1)	5 (<1)
Hispanic, Asian	7 (<1)	2 (<1)	1 (<1)
Hispanic, Pacific Islander	8 (<1)	0	0
Hispanic, Native American	10 (<1)	2 (<1)	1 (<1)
Hispanic, race unknown	440 (2)	109 (2)	98 (2)
Other	46 (<1)	21 (<1)	20 (<1)
Unknown	550 (N/A)	115 (N/A)	203 (N/A)
Recipient sex			
Male	15300 (58)	3491 (60)	2613 (60)
Female	11093 (42)	2376 (40)	1776 (40)
Karnofsky score			
10-80	8003 (30)	1887 (32)	1196 (27)
90-100	17185 (65)	3778 (64)	2715 (62)
Missing	1205 (5)	202 (3)	478 (11)
High-resolution HLA matches available out of 8			
≤5/8	761 (3)	24 (1)	27 (1)
6/8	1449 (6)	56 (2)	98 (4)
7/8	5433 (22)	740 (21)	537 (22)
8/8	16778 (69)	2730 (77)	1757 (73)
Unknown	1972 (N/A)	2317 (N/A)	1970 (N/A)

	Samples Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
Graft type			
Bone marrow	11821 (45)	2832 (48)	2352 (54)
Peripheral blood	14566 (55)	3035 (52)	2034 (46)
BM+PBSC	6 (<1)	0	3 (<1)
Conditioning regimen			
Myeloablative	16053 (61)	3586 (61)	2789 (64)
RIC	3227 (12)	739 (13)	508 (12)
Nonmyeloablative	1181 (4)	208 (4)	179 (4)
Other	5932 (22)	1334 (23)	913 (21)
Donor age at donation			
To be determined / N/A	3717 (14)	3041 (52)	2035 (46)
10-19	475 (2)	32 (1)	26 (1)
20-29	8318 (32)	895 (15)	646 (15)
30-39	7310 (28)	1064 (18)	882 (20)
40-49	5090 (19)	660 (11)	621 (14)
50+	1483 (6)	175 (3)	179 (4)
Median (range)	33 (0-69)	35 (18-65)	36 (3-59)
Disease at transplant			
AML	9204 (35)	2118 (36)	1435 (33)
ALL	4414 (17)	918 (16)	818 (19)
Other leukemia	1040 (4)	196 (3)	144 (3)
CML	3033 (11)	755 (13)	542 (12)
MDS	3463 (13)	761 (13)	537 (12)
Other acute leukemia	272 (1)	70 (1)	38 (1)
NHL	2071 (8)	427 (7)	268 (6)
Hodgkins Lymphoma	175 (1)	36 (1)	35 (1)
Plasma Cell Disorders, MM	201 (1)	56 (1)	30 (1)
Other malignancies	40 (<1)	10 (<1)	11 (<1)
Breast cancer	5 (<1)	0	0
SAA	931 (4)	207 (4)	179 (4)
Inherited abnormalities erythrocyte diff fxn	505 (2)	93 (2)	79 (2)
SCIDs	484 (2)	97 (2)	119 (3)
Inherited abnormalities of platelets	30 (<1)	5 (<1)	6 (<1)
Inherited disorders of metabolism	232 (1)	57 (1)	74 (2)
Histiocytic disorders	243 (1)	48 (1)	60 (1)
Autoimmune disorders	10 (<1)	4 (<1)	2 (<1)
Other	40 (<1)	9 (<1)	12 (<1)
Disease status at transplant			
Early	9500 (36)	2138 (36)	1389 (32)
Intermediate	4700 (18)	1078 (18)	862 (20)
Advanced	4107 (16)	928 (16)	696 (16)
Other	8086 (31)	1723 (29)	1442 (33)

	Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
Donor/Recipient CMV serostatus			
Negative / negative	6847 (26)	1310 (22)	891 (20)
Negative / positive	7405 (28)	1339 (23)	984 (22)
Positive / negative	2483 (9)	503 (9)	345 (8)
Positive / positive	4796 (18)	871 (15)	569 (13)
Unknown	4862 (18)	1844 (31)	1600 (36)
GvHD prophylaxis			
Ex vivo T-cell depletion	2013 (8)	503 (9)	416 (9)
CD34 selection	439 (2)	85 (1)	75 (2)
Cyclophosphamide	307 (1)	76 (1)	58 (1)
Tacrolimus + MMF ± others	2978 (11)	589 (10)	356 (8)
Tacrolimus + MTX ± others (except MMF)	10105 (38)	2146 (37)	1288 (29)
Tacrolimus + others (except MTX, MMF)	1213 (5)	300 (5)	138 (3)
Tacrolimus alone	532 (2)	139 (2)	76 (2)
CSA + MMF ± others (except Tacrolimus)	1567 (6)	304 (5)	295 (7)
CSA + MTX ± others (except Tacrolimus, MMF)	5569 (21)	1362 (23)	1281 (29)
CSA + others (except Tacrolimus, MTX, MMF)	558 (2)	117 (2)	154 (4)
CSA alone	217 (1)	30 (1)	75 (2)
Other GVHD prophylaxis	298 (1)	75 (1)	41 (1)
Missing	597 (2)	141 (2)	136 (3)
Donor / recipient sex match			
Male / male	9129 (40)	1830 (41)	1303 (40)
Male / female	5630 (25)	1073 (24)	737 (22)
Female / male	4138 (18)	814 (18)	660 (20)
Female / female	3973 (17)	734 (16)	595 (18)
Unknown	3523 (N/A)	1416 (N/A)	1094 (N/A)
Year of transplant			
1987	1 (<1)	0	1 (<1)
1988	54 (<1)	10 (<1)	9 (<1)
1989	147 (1)	4 (<1)	6 (<1)
1990	205 (1)	19 (<1)	30 (1)
1991	297 (1)	44 (1)	57 (1)
1992	324 (1)	40 (1)	92 (2)
1993	356 (1)	72 (1)	117 (3)
1994	444 (2)	115 (2)	112 (3)
1995	486 (2)	184 (3)	119 (3)
1996	533 (2)	231 (4)	127 (3)
1997	620 (2)	228 (4)	147 (3)
1998	578 (2)	268 (5)	132 (3)
1999	677 (3)	219 (4)	136 (3)
2000	795 (3)	155 (3)	133 (3)
2001	767 (3)	130 (2)	144 (3)

	Samples		
	Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
2002	653 (2)	120 (2)	367 (8)
2003	799 (3)	149 (3)	325 (7)
2004	1032 (4)	238 (4)	218 (5)
2005	1176 (4)	203 (3)	185 (4)
2006	1338 (5)	210 (4)	201 (5)
2007	1477 (6)	161 (3)	208 (5)
2008	1411 (5)	176 (3)	95 (2)
2009	1328 (5)	235 (4)	79 (2)
2010	1453 (6)	237 (4)	72 (2)
2011	1477 (6)	308 (5)	66 (2)
2012	1462 (6)	229 (4)	209 (5)
2013	1711 (6)	418 (7)	293 (7)
2014	1294 (5)	543 (9)	232 (5)
2015	2366 (9)	697 (12)	318 (7)
2016	1132 (4)	224 (4)	159 (4)
Follow-up among survivors, months			
N Eval	10919	2422	1743
Median (range)	51 (0-319)	37 (0-319)	56 (3-339)

Accrual Summary for First Allogeneic Transplants in CRF and TED with Samples Available for Recipient and/or Cord Blood Unit(s) through the NMDP for Cord Blood Transplants

	Samples Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
Number of patients	3649	1222	529
CRF	3185 (87)	909 (74)	380 (72)
TED	464 (13)	313 (26)	149 (28)
Number of centers	132	119	126
Recipient age at transplant			
0-9	1124 (31)	415 (34)	196 (37)
10-19	566 (16)	145 (12)	76 (14)
20-29	368 (10)	100 (8)	43 (8)
30-39	334 (9)	112 (9)	37 (7)
40-49	359 (10)	126 (10)	48 (9)
50-59	898 (25)	324 (27)	129 (24)
Median (range)	24 (0-81)	24 (0-74)	19 (0-74)
Recipient race / ethnicity			
Caucasian, non-Hispanic	2095 (60)	670 (58)	315 (63)
African-American, non-Hispanic	496 (14)	166 (14)	71 (14)
Asian, non-Hispanic	195 (6)	81 (7)	30 (6)
Pacific Islander, non-Hispanic	12 (<1)	4 (<1)	6 (1)
Native American, non-Hispanic	24 (1)	9 (1)	1 (<1)
Hispanic, Caucasian	656 (19)	208 (18)	72 (14)
Hispanic, African-American	13 (<1)	12 (1)	1 (<1)
Hispanic, Asian	1 (<1)	3 (<1)	0
Hispanic, Pacific Islander	2 (<1)	2 (<1)	0
Hispanic, Native American	16 (<1)	2 (<1)	1 (<1)
Hispanic, race unknown	1 (<1)	3 (<1)	1 (<1)
Other	0	0	1 (<1)
Unknown	138 (N/A)	62 (N/A)	30 (N/A)
Recipient sex			
Male	1999 (55)	694 (57)	289 (55)
Female	1650 (45)	528 (43)	240 (45)
Karnofsky score			
10-80	645 (18)	139 (11)	78 (15)
90-100	2244 (61)	652 (53)	270 (51)
Missing	760 (21)	431 (35)	181 (34)
High-resolution HLA matches available out of 8			
≤5/8	1800 (57)	532 (56)	224 (53)
6/8	719 (23)	238 (25)	102 (24)
7/8	394 (13)	127 (13)	67 (16)
8/8	230 (7)	59 (6)	33 (8)
Unknown	506 (N/A)	266 (N/A)	103 (N/A)

	Samples Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
Graft type			
Umbilical cord blood	3621 (99)	1188 (97)	515 (97)
BM+UCB	0	0	1 (<1)
PBSC+UCB	28 (1)	34 (3)	13 (2)
Conditioning regimen			
Myeloablative	2424 (66)	791 (65)	331 (63)
RIC	530 (15)	121 (10)	50 (9)
Nonmyeloablative	379 (10)	156 (13)	69 (13)
Other	316 (9)	154 (13)	79 (15)
Donor age at donation			
To be determined / N/A	971 (27)	1198 (98)	523 (99)
0-9	2562 (70)	0	0
10-19	105 (3)	13 (1)	4 (1)
20-29	0	1 (<1)	0
30-39	7 (<1)	4 (<1)	1 (<1)
40-49	0	2 (<1)	0
50+	4 (<1)	4 (<1)	1 (<1)
Median (range)	3 (0-68)	3 (0-68)	3 (0-52)
Disease at transplant			
AML	1426 (39)	478 (39)	181 (34)
ALL	815 (22)	278 (23)	131 (25)
Other leukemia	85 (2)	24 (2)	6 (1)
CML	113 (3)	24 (2)	12 (2)
MDS	257 (7)	82 (7)	30 (6)
Other acute leukemia	73 (2)	13 (1)	13 (2)
NHL	186 (5)	80 (7)	30 (6)
Hodgkins Lymphoma	15 (<1)	7 (1)	0
Plasma Cell Disorders, MM	7 (<1)	5 (<1)	2 (<1)
Other malignancies	7 (<1)	0	0
SAA	62 (2)	17 (1)	9 (2)
Inherited abnormalities erythrocyte diff fxn	102 (3)	50 (4)	13 (2)
SCIDs	172 (5)	60 (5)	36 (7)
Inherited abnormalities of platelets	12 (<1)	5 (<1)	4 (1)
Inherited disorders of metabolism	215 (6)	73 (6)	42 (8)
Histiocytic disorders	83 (2)	21 (2)	14 (3)
Autoimmune disorders	9 (<1)	2 (<1)	3 (1)
Other	10 (<1)	3 (<1)	3 (1)
Disease status at transplant			
Early	1359 (37)	405 (33)	166 (31)
Intermediate	779 (21)	272 (22)	118 (22)
Advanced	396 (11)	126 (10)	47 (9)
Other	1115 (31)	419 (34)	198 (37)

	Samples Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
Donor / recipient CMV serostatus			
Negative / negative	550 (15)	79 (6)	41 (8)
Negative / positive	926 (25)	115 (9)	48 (9)
Positive / negative	225 (6)	72 (6)	28 (5)
Positive / positive	531 (15)	195 (16)	53 (10)
Unknown	1417 (39)	761 (62)	359 (68)
GvHD Prophylaxis			
Ex vivo T-cell depletion	4 (<1)	2 (<1)	0
CD34 selection	44 (1)	31 (3)	19 (4)
Cyclophosphamide	2 (<1)	1 (<1)	2 (<1)
Tacrolimus + MMF ± others	1006 (28)	356 (29)	112 (21)
Tacrolimus + MTX ± others (except MMF)	143 (4)	47 (4)	21 (4)
Tacrolimus + others (except MTX, MMF)	163 (4)	51 (4)	28 (5)
Tacrolimus alone	69 (2)	23 (2)	11 (2)
CSA + MMF ± others (except Tacrolimus)	1650 (45)	520 (43)	216 (41)
CSA + MTX ± others (except Tacrolimus, MMF)	61 (2)	29 (2)	18 (3)
CSA + others (except Tacrolimus, MTX, MMF)	227 (6)	100 (8)	61 (12)
CSA alone	34 (1)	8 (1)	8 (2)
Other GVHD prophylaxis	69 (2)	19 (2)	7 (1)
Missing	177 (5)	35 (3)	26 (5)
Donor / recipient sex match			
Male / male	937 (29)	250 (29)	89 (26)
Male / female	756 (24)	186 (22)	76 (22)
Female / male	820 (26)	239 (28)	95 (28)
Female / female	687 (21)	185 (22)	80 (24)
Unknown	449 (N/A)	362 (N/A)	189 (N/A)
Year of transplant			
2000	0	2 (<1)	4 (1)
2001	5 (<1)	16 (1)	4 (1)
2002	1 (<1)	11 (1)	2 (<1)
2003	10 (<1)	23 (2)	9 (2)
2004	19 (1)	24 (2)	8 (2)
2005	69 (2)	28 (2)	15 (3)
2006	130 (4)	79 (6)	16 (3)
2007	312 (9)	21 (2)	62 (12)
2008	389 (11)	19 (2)	49 (9)
2009	478 (13)	46 (4)	37 (7)
2010	529 (14)	64 (5)	39 (7)
2011	459 (13)	110 (9)	33 (6)
2012	265 (7)	164 (13)	38 (7)
2013	322 (9)	180 (15)	40 (8)
2014	199 (5)	135 (11)	47 (9)

	Samples Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
2015	321 (9)	222 (18)	90 (17)
2016	141 (4)	78 (6)	36 (7)
Follow-up among survivors, months			
N Eval	1760	615	258
Median (range)	44 (1-149)	25 (0-170)	36 (0-193)

Accrual Summary for First Allogeneic Transplants in CRF and TED with Samples Available for Recipient and/or Donor through the NMDP for Adult Related Donor Transplants

	Samples Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
Number of patients	4473	595	239
CRF	1577 (35)	144 (24)	74 (31)
TED	2896 (65)	451 (76)	165 (69)
Number of centers	76	59	45
Recipient age at transplant			
0-9	402 (9)	32 (5)	31 (13)
10-19	430 (10)	33 (6)	24 (10)
20-29	349 (8)	65 (11)	22 (9)
30-39	345 (8)	63 (11)	16 (7)
40-49	656 (15)	93 (16)	38 (16)
50-59	2291 (51)	309 (52)	108 (45)
Median (range)	51 (0-78)	51 (0-76)	48 (0-74)
Recipient race / ethnicity			
Caucasian, non-Hispanic	2922 (67)	351 (62)	141 (61)
African-American, non-Hispanic	515 (12)	47 (8)	31 (13)
Asian, non-Hispanic	200 (5)	42 (7)	11 (5)
Pacific Islander, non-Hispanic	15 (<1)	2 (<1)	1 (<1)
Native American, non-Hispanic	13 (<1)	1 (<1)	0
Hispanic, Caucasian	644 (15)	120 (21)	45 (20)
Hispanic, African-American	19 (<1)	0	0
Hispanic, Asian	1 (<1)	0	0
Hispanic, Pacific Islander	7 (<1)	0	0
Hispanic, Native American	5 (<1)	2 (<1)	1 (<1)
Unknown	132 (N/A)	30 (N/A)	9 (N/A)
Recipient sex			
Male	2614 (58)	349 (59)	141 (59)
Female	1859 (42)	246 (41)	98 (41)
Karnofsky score			
10-80	1400 (31)	202 (34)	66 (28)
90-100	2909 (65)	374 (63)	163 (68)
Missing	164 (4)	19 (3)	10 (4)
Graft type			
Bone marrow	1156 (26)	117 (20)	62 (26)
Peripheral blood	3266 (73)	464 (78)	162 (68)
Umbilical cord blood	12 (<1)	8 (1)	10 (4)
BM+PBSC	5 (<1)	2 (<1)	0
BM+UCB	15 (<1)	3 (1)	1 (<1)
PBSC+UCB	4 (<1)	0	2 (1)
Others	15 (<1)	1 (<1)	2 (1)

	Samples Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
Conditioning regimen			
Myeloablative	1579 (35)	227 (38)	84 (35)
RIC	491 (11)	40 (7)	28 (12)
Nonmyeloablative	197 (4)	31 (5)	14 (6)
Other	2206 (49)	297 (50)	113 (47)
Donor age at donation			
To be determined / N/A	2919 (65)	458 (77)	174 (73)
0-9	118 (3)	10 (2)	5 (2)
10-19	114 (3)	3 (1)	9 (4)
20-29	183 (4)	15 (3)	6 (3)
30-39	175 (4)	16 (3)	6 (3)
40-49	246 (5)	25 (4)	9 (4)
50+	718 (16)	68 (11)	30 (13)
Median (range)	48 (0-81)	50 (0-79)	47 (2-73)
Disease at transplant			
AML	1452 (32)	209 (35)	68 (28)
ALL	657 (15)	100 (17)	35 (15)
Other leukemia	119 (3)	24 (4)	6 (3)
CML	171 (4)	17 (3)	10 (4)
MDS	704 (16)	84 (14)	28 (12)
Other acute leukemia	57 (1)	8 (1)	3 (1)
NHL	528 (12)	65 (11)	33 (14)
Hodgkins Lymphoma	103 (2)	16 (3)	10 (4)
Plasma Cell Disorders, MM	145 (3)	25 (4)	11 (5)
Other malignancies	14 (<1)	0	0
Breast cancer	1 (<1)	0	0
SAA	182 (4)	18 (3)	13 (5)
Inherited abnormalities erythrocyte diff fxn	222 (5)	24 (4)	14 (6)
SCIDs	75 (2)	3 (1)	5 (2)
Inherited abnormalities of platelets	6 (<1)	1 (<1)	0
Inherited disorders of metabolism	8 (<1)	1 (<1)	0
Histiocytic disorders	22 (<1)	0	1 (<1)
Autoimmune disorders	1 (<1)	0	1 (<1)
Other	6 (<1)	0	1 (<1)
Disease status at transplant			
Early	1540 (34)	221 (37)	72 (30)
Intermediate	455 (10)	51 (9)	21 (9)
Advanced	620 (14)	88 (15)	29 (12)
Other	1858 (42)	235 (39)	117 (49)
Donor / recipient CMV serostatus			
Negative / negative	652 (15)	68 (11)	24 (10)
Negative / positive	768 (17)	77 (13)	36 (15)

	Samples Available for Recipient and Donor	Samples Available for Recipient Only	Samples Available for Donor Only
Positive / negative	346 (8)	29 (5)	17 (7)
Positive / positive	1336 (30)	162 (27)	67 (28)
Unknown	1371 (31)	259 (44)	95 (40)
GvHD Prophylaxis			
Ex vivo T-cell depletion	50 (1)	5 (1)	6 (3)
CD34 selection	50 (1)	13 (2)	2 (1)
Cyclophosphamide	410 (9)	49 (8)	14 (6)
Tacrolimus + MMF ± others	617 (14)	44 (7)	28 (12)
Tacrolimus + MTX ± others (except MMF)	1959 (44)	219 (37)	93 (39)
Tacrolimus + others (except MTX, MMF)	406 (9)	143 (24)	30 (13)
Tacrolimus alone	53 (1)	8 (1)	1 (<1)
CSA + MMF ± others (except Tacrolimus)	139 (3)	14 (2)	9 (4)
CSA + MTX ± others (except Tacrolimus, MMF)	349 (8)	31 (5)	26 (11)
CSA + others (except Tacrolimus, MTX, MMF)	39 (1)	8 (1)	3 (1)
CSA alone	37 (1)	4 (1)	1 (<1)
Other GVHD prophylaxis	48 (1)	9 (2)	2 (1)
Missing	316 (7)	48 (8)	24 (10)
Donor / recipient sex match			
Male / male	1390 (33)	198 (36)	65 (31)
Male / female	917 (22)	97 (18)	46 (22)
Female / male	1088 (26)	127 (23)	55 (26)
Female / female	863 (20)	131 (24)	43 (21)
Unknown	215 (N/A)	42 (N/A)	30 (N/A)
Year of transplant			
2007	23 (1)	4 (1)	0
2008	147 (3)	10 (2)	8 (3)
2009	203 (5)	28 (5)	6 (3)
2010	267 (6)	39 (7)	9 (4)
2011	396 (9)	55 (9)	27 (11)
2012	528 (12)	74 (12)	36 (15)
2013	677 (15)	107 (18)	31 (13)
2014	870 (19)	120 (20)	51 (21)
2015	824 (18)	97 (16)	40 (17)
2016	538 (12)	61 (10)	31 (13)
Follow-up among survivors, months			
N Eval	2753	348	138
Median (range)	24 (0-113)	24 (3-101)	24 (3-95)